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A B S T R A C T
Purpose: Seizures and antiepileptic drugs (AED) may disrupt sleep patterns in patients with epilepsy,
thus evaluation of lacosamide effects on objective and subjective sleep measures is warranted.
Methods: A multicenter, interventional, open-label study (NCT01530386) was conducted in healthy
subjects without confounding effects of concomitant AED use, co-morbidities, or disease state to
determine whether lacosamide impacts sleep parameters after 22 days of lacosamide exposure. After
overnight polysomnography (PSG) to assess baseline parameters, lacosamide was initiated at 100 mg/
day (50 mg twice daily) and increased by 100 mg/day weekly to 300 mg/day (the mid-range
maintenance dose for adjunctive therapy). The primary variable was change from baseline to post-
treatment in wake after sleep onset (WASO). Secondary variables included additional objective sleep
measures, subject-reported measures of sleep quality, daytime sleepiness, and tolerability. Change from
baseline in WASO was analyzed using the Wilcoxon rank-sum test.
Results: A total of 27 subjects received 1 dose of lacosamide and 25 subjects completed the study. For
WASO, median change from baseline was a 6-min reduction (95% conﬁdence interval: 38, 77.5;
p = 0.1074) after lacosamide treatment; this was considered not clinically relevant. No clinically relevant
changes were observed in any secondary variables. Thirteen subjects (48%) reported a treatment-
emergent adverse event, none of which was severe or led to study discontinuation.
Conclusion: Lacosamide 300 mg/day had no effect on objective or subjective sleep parameters in healthy
subjects and was generally well tolerated.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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A complex relationship exists between epilepsy and sleep.
Seizure activity is often associated with speciﬁc phases of the
sleep/wake cycle, and sleep deprivation can precipitate seizure
activity.1,2 Inadequate or fragmented sleep, excessive daytime
sleepiness, and decreased quality of life are often reported by
patients with epilepsy and may be due to the presence or
occurrence of seizures. Many antiepileptic drugs (AED) inﬂuence
sleep parameters 2–9 and sleep architecture.10 Negative effects on* Corresponding author. Tel.: +1 512 420 9900; fax: +1 512 420 9944.
E-mail addresses: jdh@sleepdoc.net (J.D. Hudson), jeffrey.guptill@duke.edu (J.T.
Guptill), Bill.Byrnes@ucb.com (W. Byrnes), Stephen.Yates@ucb.com (S.L. Yates),
Paulette.Williams@ucb.com (P. Williams), oneill_dcruz@yahoo.com (O. D’Cruz).
http://dx.doi.org/10.1016/j.seizure.2014.10.012
1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights resleep associated with some AEDs include an increased percentage
of light sleep, and reduced rapid eye movement (REM) and/or
slow wave sleep (Stage 3).7,11–13 AEDs may also cause daytime
somnolence, fatigue, or drug-induced insomnia.2,7,11–14 Since sleep
disturbances signiﬁcantly impair quality of life in patients with
epilepsy,15,16 formal assessment of the effects of AEDs on sleep
parameters in individuals with and without epilepsy helps to
identify any drug-induced impact on sleep and distinguish drug
effects from a variety of medication and disease-related con-
founding factors. In addition, a better understanding of the effects
of AEDs on sleep parameters may provide clinicians further
information necessary for optimal AED selection.1 Hence, a formal
evaluation of the effects of lacosamide on sleep parameters was
conducted in this study with healthy individuals.
Lacosamide is approved for monotherapy and adjunctive
therapy of partial-onset seizures in patients 17 years of age andserved.
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(16–18 years of age) patients in the European Union.17,18 The
recommended maintenance dose is 200–400 mg/day for adjunc-
tive therapy and the World Health Organization daily deﬁned dose
is 300 mg/day.19 Lacosamide acts via a novel mechanism of action,
through selective enhancement of slow inactivation of voltage-
gated sodium channels.20,21 Efﬁcacy and tolerability of lacosamide
as adjunctive AED treatment was demonstrated in 3 pivotal Phase
2b/3 studies.22–24 The most frequently reported treatment-
emergent adverse events in these studies were associated with
the central nervous system (dizziness and headache) and
gastrointestinal tract (nausea), while fatigue and somnolence
were reported at lower rates across doses of 200–600 mg/day.22–24
To date, effects of lacosamide on sleep have not been formally
assessed via objective assessment such as polysomnography
(PSG); therefore, this study sought to evaluate whether lacosamide
has any impact on objective and subject-rated measures of sleep.
Evaluating the effects of AEDs on sleep in healthy subjects has
the beneﬁt of distinguishing drug effects on sleep with fewer
confounding variables. These individuals, unlike patients with
epilepsy, do not take concomitant AEDs, experience seizures, or
have co-morbidities that could affect sleep parameters. This
evaluation was conducted in healthy subjects utilizing overnight
PSG (7–8 h). The primary objective was to evaluate the effects of
lacosamide 300 mg/day (the mid-range approved dose) on wake
after sleep onset (WASO) in healthy subjects after 3 weeks of
exposure. Secondary objectives included evaluating the effect of
lacosamide on additional objective sleep measures, subject-
reported measures of sleep quality, and tolerability.
2. Materials and methods
This was an open-label study conducted at 3 clinical sites in the
US (ClinicalTrials.gov identiﬁer: NCT01530386; SP1031). This
study was conducted in accordance with the applicable regulatory
and International Conference on Harmonisation Good Clinical
Practice requirements and local laws. All subjects provided written
informed consent prior to participation in the study.
2.1. Subjects
Healthy men and women aged 18–50 years with body weight
(body mass index [BMI] 18 kg/m2 and 28 kg/m2) and good sleep
hygiene with normal bedtime between 9:00 PM and 1:00 AM were
eligible for inclusion. Subjects had no clinically relevant cardio-
vascular, renal, gastrointestinal, hepatic, metabolic, endocrine,
neurological, or psychiatric abnormalities, and were in general
good health.
Key exclusion criteria were history of or a PSG during screening
revealing primary sleep disorders such as sleep apnea syndrome
(including moderate-to-severe obstructive sleep apnea or an
apnea-hypopnea index [AHI] >8) or narcolepsy, have a known
hypersensitivity to any component of lacosamide, or taking
concomitant medications within 2 weeks prior to the ﬁrst day
of dosing (except non-steroidal anti-inﬂammatory drugs, oral
contraceptives, and non-psychoactive supplements; short-term
use of medications for symptomatic relief was permitted but not
within 3 days prior to the PSG). In addition, subjects who were
smokers, had a history of alcohol or drug abuse or test positive on
alcohol breath test or urine drug screen, were pregnant or nursing,
or consumed >400 mg of caffeine/day or 40 g alcohol/day; had
clinically relevant hematology or clinical chemistry parameters,
physical examination or vital signs, or cardiac condition; or had a
lifetime history of suicide attempt or suicidal ideation in the past 6
months, or any medical or psychiatric condition that, in the
opinion of the investigator, could have jeopardized or would havecompromised the subject’s ability to participate in this study were
excluded.
2.2. Study design
The study consisted of a screening period of up to 21 days, a 22-
day treatment period, and a taper/safety follow-up. Screening was
conducted over 3 visits: at Visit 1 (Day 21 [21 days before ﬁrst
administration of treatment]), subjects were evaluated for
eligibility for enrollment into the study; Visit 2 (Day 2) consisted
of the initial pre-treatment overnight PSG for an adaptation night
of recording; and Visit 3 (Day 1) was the second pre-treatment
overnight PSG followed by additional subjective sleep assessments
the morning after as baseline sleep measurements.
Subjects began lacosamide treatment (Day 0) after completing
the second pre-treatment overnight PSG during Visit 3. Lacosa-
mide was provided as 50 mg and 100 mg tablets using the
commercial formulation (UCB Pharma, Smyrna, GA). Tablets were
taken in equally divided doses approximately 12 h apart, with the
evening dose 2–3 h before bedtime. The initial dose was
lacosamide 100 mg/day (lacosamide 50 mg twice daily) for 7
days, increased weekly by 100 mg/day to a target dose of
lacosamide 300 mg/day [150 mg twice daily]). Dose reductions
were not allowed; subjects who could not tolerate the lacosamide
300 mg/day dose were withdrawn.
After subjects had maintained a dose of lacosamide 300 mg/day
for a period of 7 continuous days, Visit 4 (Day 21) was conducted,
which included the ﬁrst of the post-treatment overnight stays with
PSG. On Visit 5 (Day 22), the second post-treatment overnight was
conducted and subjects began a 2-day taper during which time
they were to decrease the dose of lacosamide by 100 mg/day.
Subjects returned for a safety follow-up at Visit 6 (Day 30).
2.3. Assessments
Overnight in-laboratory PSG recordings were conducted using
standard methods for 7–8 h. Scoring of PSG tracings were
performed in strict accordance with the criteria of the American
Academy of Sleep Medicine Manual for Scoring Sleep by a central
reader.25,26 The international 10–20 electrode placement system
was used for recording an electroencephalogram (ECG; F3, F4, C3,
C4, O1, O2, M1, M2), electro-oculography (E1, E2), chin electro-
myogram, leg electromyogram, ECG, respiratory effort (chest and
abdomen), pulse oximetry, and airﬂow (nasal pressure transducer
and thermistor). Sleep staging, respiratory events (e.g., apneic
events, hypopneic events), periodic limb movements, and arousals
were scored at 30-s epochs on a high-resolution monitor.
Hypopneas were scored according to rule VII.4.B (3%).25
Readings from the second night of the PSG were used for
analysis. PSG recordings for the second overnight PSG assessment
were initially scored by a certiﬁed scorer at the investigative site,
so as to immediately determine the subject’s eligibility to enroll in
the treatment period of the study before they were sent to the
central reader. Data from each ﬁrst overnight assessment was
considered as an adaptation to the sleep laboratory; therefore, sites
were not required to score or send these ﬁles to the central reader
for review unless the second overnight assessment was inadequate
or not valid for evaluation.
The primary pharmacodynamic variable was change in WASO
from baseline to the end of treatment as measured by PSG. WASO is
a measure of sleep disruption and fragmentation, which may be
associated with effect of seizures and medications in patients with
epilepsy.5,10WASO was deﬁned as the total time that was scored as
awake in a PSG occurring between sleep onset and ﬁnal wake up.
Secondary PSG assessments were total sleep time (TST), sleep
efﬁciency, percentage of sleep spent in each sleep stage (1, 2, 3, and
Table 1
Subject disposition and demographics, safety set.
All subjects (N = 27)
Disposition, n (%)
Completed study 25 (92.6)
Discontinued 2 (7.4)
Reason for discontinuation
Adverse event 1a (3.7)
Consent withdrawn 1 (3.7)
Demographics
Age, years, median (range) 28.0 (18.0–48.0)
Male, n (%) 16 (59.3)
Race, n (%)
Black 2 (7.4)
White 25 (92.6)
Ethnicity, n (%)
Hispanic or Latino 2 (7.4)
BMI, kg/m2, mean (SD) 23.6 (2.63)
Apnea-hypopnea index, median (range) 0.5220 (0, 4.377)
BMI, body mass index.
a One subject discontinued due to adverse events of increased alanine
aminotransferase and aspartate aminotransferase at baseline. The subject had
been treated with lacosamide 100 mg/day for 3 days prior to receiving information
that baseline liver values were out of range.
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sleep, arousal index (AI), AHI, and periodic limb movement index
(PLMI) using standard accepted deﬁnitions.
Subject-rated pharmacodynamic variables were the Epworth
sleepiness scale (ESS) and the Pittsburgh sleep quality inventory
(PSQI); these assessments were collected following the second
overnight PSG pre- and post-treatment. The ESS was used to
evaluate daytime sleepiness, and ranges from 0 to 24, where higher
scores indicate more sleepiness and scores 0–9 are considered
normal.27 The PSQI, which is used to assess sleep quality
and disturbances, gives a global score (sum) of 7 components
(each component has a range between 0 and 3 [overall global
range: 0–21]; higher score indicates higher impairment, and scores
>5 indicate poor sleep quality with severe difﬁculties in 2
components or moderate difﬁculties in >3 components).28
Tolerability was assessed by incidence of adverse events
(including treatment-emergent adverse events and serious ad-
verse events) that occurred during the study; subject withdrawal
due to adverse events; changes in laboratory measurements,
including hematology, clinical chemistry, and urinalysis param-
eters; changes in vital signs (including body weight); changes in
12-lead ECGs; suicidality (at screening as well as any suicidal
ideation and behavior during the study) as assessed by using the
Columbia-suicide severity rating scale29; and changes in neuro-
logical exam ﬁndings.
2.4. Analysis
Statistical analyses were performed using SAS version 9.13 (SAS
Institute Inc., Cary, NC). Pharmacodynamic variables were
evaluated for the full analysis set (all subjects who completed
the PSG at baseline and end of the 3-week treatment). The planned
analysis of the primary pharmacodynamic variable (change from
baseline to end of treatment in WASO) was a paired t-test with a 2-
sided signiﬁcance of 0.05; however, results from 3 subjects
indicated larger amounts of time spent awake during the PSG
assessments compared with other subjects, although no proce-
dural deviations were found. The resulting data was not normally
distributed both at baseline and end of treatment; therefore, the
planned t-test was not the most appropriate statistical test. A
Wilcoxon rank-sum test was performed. Additionally, descriptive
statistics on the percent change from baseline in WASO were
calculated. For all secondary pharmacodynamic variables (sleep
efﬁciency and TST), the 95% conﬁdence interval (CI) around the
median was calculated because of non-normally distributed data
at both the baseline and end of treatment, and presented in
addition to the planned 95% CI around the mean. For all other
pharmacodynamic variables, only the planned 95% CI around the
mean was presented. Safety outcomes were evaluated using the
safety set (all subjects who received 1 dose of lacosamide).
It was prospectively estimated that a minimum of 19 subjects
in the full analysis set would provide 90% power to detect a
difference in means of 8.0 min in WASO, assuming a SD of the
difference of 10.0 using a paired t-test with a 2-sided signiﬁcance
level of 0.05; this was based on ﬁndings of an 8 min difference in
WASO between levetiracetam and carbamazepine in patients with
epilepsy.30 To adjust for potential drop outs, approximately 25
subjects were to be enrolled. No imputation of missing values for
analysis parameters was performed.
3. Results
Disposition and baseline demographics for the 27 subjects who
received 1 dose of lacosamide (safety set) are shown in Table
1. Baseline demographic characteristics of the 25 subjects who
completed the study (full analysis set) were similar to the safetyset. The majority of subjects followed the dose titration and
tapering regimen; however, in 3 subjects, dose titration and
tapering regimen differed from the administration regimen and 1
subject was consistently noncompliant in completing the drug
dosing log.
3.1. Pharmacodynamic assessments
No clinically meaningful changes in sleep parameters were
recorded with lacosamide 300 mg/day (Table 2). Median WASO
decreased by 6 min (95% CI: 38, 77.5; 34.4% decrease) from
baseline to end of treatment; this change was not statistically
signiﬁcant (p = 0.1074). Secondary pharmacodynamic variables of
sleep efﬁciency, TST, and sleep latency also did not show any
clinically relevant changes (Table 2). The percentage of time spent
in stage 1 and stage 2 decreased slightly (by 0.38% and 2.37%,
respectively), while the percentage of time spent in stage 3 and
stage REM increased slightly (by 2.35% and 0.40%, respectively)
after lacosamide treatment. No changes in AI, AHI, or PLMI were
observed.
Mean values were in the normal range on the ESS and in the
good sleep quality range on the PSQI at baseline, with no
meaningful changes after lacosamide treatment (Table 2).
3.2. Safety and tolerability
Treatment-emergent adverse events were reported by 13
subjects (48.1%; Table 3). Twelve subjects (44.4%) had treat-
ment-emergent adverse events that were considered drug-related
by the investigator. The most common adverse events, each
reported by 3 subjects (11.1%), were affect lability, headache, and
somnolence. No deaths occurred.
All treatment-emergent adverse events were mild to moderate
in severity. One subject experienced an adverse event of increased
eosinophil count (no symptoms reported) that was initially
classiﬁed as serious; however, none of the protocol-deﬁned
criteria for seriousness was met.
No subjects discontinued from the study due to adverse events
related to lacosamide. One subject discontinued the study 3 days
after initiation of lacosamide at 100 mg/day due to elevated alanine
aminotransferase and aspartate aminotransferase reported on
baseline safety assessments. This subject had received lacosamide
100 mg/day for 3 days prior to receiving the information that
baseline liver values before starting lacosamide were out of range;
Table 2
Summary of changes in sleep parameters in healthy subjects before and after treatment with lacosamide 300 mg/day (N = 25, full analysis set).
Clinical and sleep parametersa Baseline After lacosamide Change from baseline (95% CI)
Polysomnographic ﬁndingsb
WASO, min 23.50 (8–75.5) 13.50 (4.5–144.5) 6.00 (range: 38 to 77.5)
p = 0.1074
Sleep efﬁciency, % 92.71 (70.14–96.93) 93.32 (52.5–98.02) 1.03 (2.40, 2.40)
Total sleep time, min 419.0 (326.5–460) 423.0 (252–468) 1.50 (19.00, 16.00)
Sleep onset latency, min 8.0 (0.5–18.5) 5.5 (0–26) 1.50 (range: 11.5 to 22)
Latency to persistent sleep, min 11.0 (0.5–100) 10.5 (0–84) 0.5 (range: 98 to 66)
REM latency, min 97.50 (56–271.5) 85.00 (48–279.5) 18.00 (range: 131 to 122.5)
Stage 1, % 7.41  3.69 7.03  3.40 0.38 (1.30, 0.54)
Stage 2, % 52.86  8.27 50.49  8.11 2.37 (4.78, 0.04)
Stage 3, % 22.60  8.28 24.95  9.28 2.35 (0.03, 4.67)
Stage REM, % 17.14  3.89 17.54  3.44 0.40 (1.20, 2.00)
AI, events/h 7.71  4.98 8.030  3.51 0.32 (1.49, 2.13)
AHI, events/h 0.79  0.98 0.92  0.72 0.14 (0.33, 0.60)
PLMI, events/h 2.19  3.09 1.52  3.13 0.68 (2.08, 0.73)
Subject-rated
ESS, global score 5.5  3.2 6.1  4.1 0.6 (0.57, 1.77)
PSQI, total score 4.4  2.5 4.1  1.8 0.3 (1.23, 0.67)
AHI, apnea-hypopnea index; AI, arousal index; CI, conﬁdence interval; ESS, Epworth sleepiness scale; PLMI, periodic limb movement index; PSQI, Pittsburgh sleep quality
inventory; REM, rapid eye movement; WASO, wake after sleep onset.
a Data are presented as median (range) for WASO, sleep efﬁciency and total sleep time or mean  SD unless otherwise indicated.
b Each overnight PSG was recorded for a minimum of 7 h and a maximum of 8 h.
Table 3
Incidence of treatment-emergent adverse events, safety set.
n (%) N = 27
Any treatment-emergent adverse event 13 (48.1)
Serious treatment-emergent adverse event 1a (3.7)
Discontinuations due to treatment-emergent
adverse eventb
0
Treatment-emergent adverse events occurring
in >1 subject
Affect lability 3 (11.1)
Headache 3 (11.1)
Somnolence 3 (11.1)
Dizziness 2 (7.4)
Feeling abnormal 2 (7.4)
Non-cardiac chest pain 2 (7.4)
a A serious adverse event of eosinophil count increased (no symptoms reported)
was reported for 1 subject; however, no protocol-deﬁned seriousness criteria were
met.
b One subject discontinued due to adverse events of increased alanine
aminotransferase and aspartate aminotransferase levels, which occurred prior to
treatment with lacosamide, but the event was not treatment-emergent since no
study drug had been taken at the time of elevation.
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taken at the time of elevation. Another subject withdrew consent
after 7 days of treatment with lacosamide 100 mg/day. One
treatment-emergent adverse event of bradycardia was reported
in a subject (an athlete) who also had a pre-treatment ﬁnding of
bradycardia. Bradycardia was detected by ECG and reported as not
related to the study drug, and the lacosamide dose was not changed
due to the bradycardia.
Overall, there were no clinically relevant changes in mean
laboratory parameters, vital signs, ECG measurements, or neuro-
logical ﬁndings. No subjects reported having suicidal ideation or
behavior as assessed by the Columbia-suicide severity rating scale.
4. Discussion
The results of the current study indicate that lacosamide
300 mg/day did not negatively impact or substantially change any
objective sleep measures assessed by PSG, including WASO and
other sleep parameters. Moreover, since scores on the ESS and PSQI
were not signiﬁcantly different after lacosamide treatment as
compared with baseline, no meaningful change was noted insubject-rated daytime sleepiness or sleep quality. Overall,
lacosamide 300 mg/day was well tolerated and the safety proﬁle
was consistent with that seen in other studies in healthy
subjects.31–33 These results are consistent with other evidence
that lacosamide has a good tolerability proﬁle.22–24,34,35
The impact that AEDs can have on sleep in patients with
epilepsy is well documented, although results vary widely based
on the agent, whether acute or long-term effects were evaluated,
disease severity, and use of concomitant medications.1,3–5 In
general, older AEDs such as benzodiazepines, barbiturates, and
phenytoin have a demonstrated negative impact on sleep
parameters, such as a reduction in the amount of time spent in
REM sleep and an increase in subject-reported daytime sleepi-
ness.3,4 Acute detrimental effects of carbamazepine such as
increased sleep fragmentation and reduced time spent in REM
sleep have been reported, but these are no longer present when
sleep was evaluated after 1 month of carbamazepine treatment.7
Fewer sleep-related side effects are seen with newer AEDs, albeit
some effects have been noted with conﬂicting results. Some
second-generation AEDs, such as gabapentin and pregabalin,
enhance slow wave sleep.4 Levetiracetam data are conﬂicting,
generally showing no major effects on objective measures of sleep,
but potentially leading to some consolidation of sleep.36–38
Many variables impact quality of life in patients with epilepsy,
and sleep disturbance and poor quality sleep are known to have a
negative impact, but often go unrecognized in a clinical
setting.15,16,39 For example, one survey of patients with epilepsy
found that 16.9% of respondents reported excessive daytime
sleepiness, 28.2% reported obstructive sleep apnea, and 24.6%
reported insomnia, all of which were associated with signiﬁcant
reductions on the quality of life in epilepsy inventory.16 No data
reporting how physicians evaluate or consider sleep when treating
epilepsy have been published to date.
The lack of signiﬁcant impact on subjective sleep parameters
noted in the current study is consistent with results from a recent
10-patient open-label study, which indicated that adding lacosa-
mide to an existing treatment regimen for refractory focal epilepsy
did not signiﬁcantly affect self-reported sleep quality or daytime
sleepiness.40 These data suggest that our observations may extend
to subjective assessments of sleep in patients with epilepsy.
Further study in patients with different types of epilepsy should be
conducted to assess whether lacosamide has any impact on
objective or subjective sleep parameters, including arousals, stage
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lacosamide treatment has any beneﬁcial effects on sleep, such as
reducing sleep fragmentation due to reducing nocturnal seizures.
One limitation of this study is that this was an open-label study.
Several reports have demonstrated a signiﬁcant expectation effect
on subjective and objective sleep parameters in individuals with
insomnia, as well as in healthy subjects.41–43 However, it is unlikely
this occurred in the current study, as no signiﬁcant positive or
negative effects were seen in any of the sleep parameters.
In conclusion, results of the current study indicate that
lacosamide does not signiﬁcantly affect sleep parameters in
healthy subjects and is associated with a generally low incidence
of intolerable adverse effects. To date, this is the ﬁrst formal
evaluation of the effects of lacosamide on sleep in healthy subjects.
Further investigations to assess effects of lacosamide on sleep
parameters in patients with epilepsy are required given their
potential impact on quality of life and seizure control.
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